Research

We have six important clinical trials at Retina Associates of Florida. We are currently enrolling patients in the following studies: WET AMD: LADDER trail, Diabetic Retinopathy - DRCR Protocol U trial, and DRCR Protocol AB trial.

  • DRY AMD: currently enrolling
    Metformin trial (University of California/SanFrancisco)
    COMPARES: Metformin vs control
    ELIGIBILITY: Patients with areas of geographic atrophy and good visual acuity
    DURATION: 2 years
    QUESTION: Does metformin reduce rate of vision loss and progression?
  • WET AMD: enrollment complete
    LADDER trail (Genentech/Roche)
    COMPARES: Lucentis Port Delivery System Implant (PDS) with 3 different doses of Lucentis
    ELIGIBILITY: Patients will be randomized to one of 3 doses of Lucentis in a port delivery system implant
    DURATION: 2 years
    QUESTION: Time until PDS needs refilling in 3 different doses of Lucentis with implant
  • WET AMD: enrollment completed
    Darpin Abicipar trial (Allergan)
    COMPARES: Abicipar Q8wk vs Abicipar Q12wk vs Lucentis Q4 wks
    ELIGIBILITY: Patients will be randomized to one of three groups with newly diagnosed wet AMD with vision 20/40 – 20/320.
    DURATION: 2 years
    QUESTION: Is Abicipar dosed at Q8 or Q12 wk noninferior to Lucentis Q4 wk
  • DIABETIC RETINOPATHY: enrollment completed
    DRCR Protocol U trial

    COMPARES: Lucentis (Anti-VEGF) + Dexamethasone (steroid) vs Lucentis alone ELIGIBILITY: Patients will be randomized to combination therapy vs monotherapy for recurrent diabetic macular edema and at least 6 previous injections of Anti-VEGF with vision of 20/30 – 20/300. Patients must have had previous cataract surgery.
    DURATION: 12 months
    QUESTION: Which treatment is best for preserving good visual acuity?
  • DRCR Protocol V trial: enrollment completed
    COMPARES: Macular Laser + Lucentis vs Prompt Lucentis (Anti-VEGF) vs Observation and deferred Lucentis
    ELIGIBILITY: New diagnosis of diabetic macular with vision of 20/25 or better.
    DURATION: 2 years
    QUESTION: Which treatment is best for preserving good visual acuity?
  • DRCR Protocol AB trial: enrollment completed
    COMPARES: Intravitreal Eylea vs Vitrectomy for Vitreous Hemorrhage from PDR
    ELIGIBILITY: Vision of 20/32 or worse.
    DURATION: 2 years
    QUESTION: Which treatment provides best vision at 24 weeks?
  • DRCR Protocol W trial: currently enrolling
    COMPARES: Periodic anti vegf injections vs observation for prevention of vision threatening Diabetic Retinopahty in eyes at high risk.
    ELIGIBILITY: Vision of 20/25 or better with severe NPDR.
    DURATION: 4 years
    QUESTION: Do periodic anti vegf injections delay the onset of Proliferative diabetic Retinopathy in patients @ high risk?

The trials are sponsored, so eligible patients will not incur additional costs. We encourage you to refer eligible patients as they would benefit from the studies and help us answer important questions.

Questions: Contact Janet @ RAF 813.875.6373 ext 239 or email Janet